Depakote (divalproex sodium) causes frequent digestive side effects like nausea and vomiting, along with drowsiness, tremor, and weight gain. It also carries rare but serious risks to the liver and pancreas, which is why the FDA requires its strongest safety warnings on the label. The side effects you experience depend partly on what condition you’re taking it for and how high your dose is.
The Most Common Side Effects
Nausea is the single most reported side effect across all uses. In epilepsy trials, nearly half of patients taking Depakote as an add-on therapy reported nausea, and about a third experienced it when using the drug alone. For migraine prevention, the rate is lower, around 15%, likely because the doses tend to be smaller.
Other frequent side effects include:
- Drowsiness: affects 17% to 30% of patients depending on the condition being treated, compared to 5% to 12% on placebo
- Tremor: ranges from 9% in migraine patients up to 57% in epilepsy patients on higher doses
- Vomiting: reported in 7% to 27% of patients
- Dizziness: around 25% in epilepsy trials
- Abdominal pain and diarrhea: each in the range of 7% to 23%
- Weakness and fatigue: 21% to 27% in epilepsy patients
Many of these digestive symptoms are worst in the first few weeks and improve as your body adjusts. Taking Depakote with food or using the extended-release formulation can help reduce stomach upset.
Weight Gain
Among mood stabilizers and anticonvulsants, Depakote is one of the most likely to cause weight gain. The Mayo Clinic identifies it as the bipolar medication most associated with this problem. Weight gain tends to develop gradually over months and can be significant enough to affect how people feel about staying on the medication long term. Eating well and staying physically active can help, but for some people the gain persists regardless.
Hair Loss
Up to 12% of people taking Depakote experience some degree of hair thinning or loss. The risk is dose-related: at higher doses, the rate climbs to roughly 28%, while lower doses carry less risk. The hair loss is usually temporary and tends to occur during long-term use. Hair typically grows back after the dose is reduced or the medication is stopped, though the texture may change slightly when it returns.
Cognitive Effects and Brain Fog
Some people on Depakote describe feeling mentally slower or foggy. In clinical trials, “thinking abnormalities” were reported by 1% to 5% of patients being treated for mania or migraines, and by 6% of epilepsy patients on combination therapy (compared to none on placebo). Memory problems showed up in about 7% of epilepsy patients on higher doses. Combined with the drowsiness that affects up to 30% of users, these cognitive effects can make it harder to concentrate at work or feel sharp during daily tasks.
Effects on Blood Cells
Depakote can lower your platelet count, which means your blood may not clot as well as it should. In one study of psychiatric patients, about 28% experienced at least one episode of low platelets. The risk is notably higher for older adults: over half of elderly patients in the same study had low platelet counts at some point during treatment. One elderly patient on a blood thinner developed spontaneous facial bleeding, and a 68-year-old woman’s platelet count dropped dangerously low before the drug was stopped.
This is why blood counts and clotting tests are recommended before starting Depakote and at regular intervals afterward, especially before any planned surgery.
Hormonal Effects in Women
Women taking Depakote face roughly three times the risk of developing polycystic ovary syndrome (PCOS) compared to women on other anticonvulsants. A meta-analysis of 11 studies found that women on the drug were also about twice as likely to show polycystic ovaries on ultrasound and more than twice as likely to have elevated male hormones. Menstrual irregularities were significantly more common too, affecting more women on Depakote than those on alternative medications.
These hormonal changes can affect fertility and cause symptoms like acne, excess body hair, and irregular or absent periods. For women of reproductive age, this is an important factor when weighing Depakote against other treatment options.
Liver Damage
The FDA’s strongest warning on Depakote’s label concerns the risk of serious, potentially fatal liver damage. Children under two years old face the highest risk, particularly those on multiple seizure medications or those with underlying metabolic disorders or developmental disabilities. People with certain inherited mitochondrial conditions are also at elevated risk.
Liver damage can begin with vague symptoms that are easy to dismiss: general tiredness, weakness, facial swelling, loss of appetite, and vomiting. In epilepsy patients, a sudden return of seizures can also signal liver trouble. Liver function tests are recommended before starting treatment and frequently during the first six months, when the danger is greatest.
Pancreatitis
Life-threatening inflammation of the pancreas has been reported in both children and adults on Depakote, earning it a second boxed warning from the FDA. The key symptoms to recognize are severe abdominal pain, nausea, vomiting, and loss of appetite. These overlap with the drug’s common side effects, which makes pancreatitis easy to miss in its early stages. Abdominal pain that is sudden, severe, or persistent warrants immediate medical evaluation.
Risks During Pregnancy
Depakote carries the most serious pregnancy risks of any commonly used anticonvulsant. Approximately 10% of babies exposed to the drug in the womb are born with physical malformations. Beyond structural birth defects, 30% to 40% of exposed children experience developmental delays, including late walking, late talking, poor language skills, and memory difficulties. By age six, children with prenatal exposure score an average of 7 to 10 IQ points lower than children exposed to other epilepsy medications.
The risks extend to neurodevelopmental conditions as well. Prenatal exposure increases the risk of autism spectrum disorder roughly threefold and childhood autism roughly fivefold compared to the general population. There is also evidence of increased risk for ADHD symptoms. These findings have led regulatory agencies worldwide to restrict Depakote use in women who could become pregnant unless no alternative treatment is effective.
Routine Monitoring While on Depakote
Because of the range of serious risks, taking Depakote involves regular blood work. Liver function tests are critical in the first six months. Complete blood counts and clotting tests help catch platelet problems early. If the medication doesn’t seem to be working well, your blood levels of the drug can be checked to see if they fall within the therapeutic range of 50 to 100 micrograms per milliliter. Drug levels also need rechecking if you start or stop other medications, since many drugs interact with Depakote and change how your body processes it.